KEVIN ASONGLEFAC: Open Payments
NPI 1770139370 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$434 in 21 payments from 9 companies in 2025. Trend: 2023 $112 · 2024 $310 · 2025 $434
Food & beverage: $434
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 5 | $134 |
| Ferring Pharmaceuticals Inc. | 5 | $94 |
| Endo USA, Inc. | 3 | $58 |
| ABBVIE INC. | 2 | $45 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $31 |
| UROGEN PHARMA, INC. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $17 |
| BIOPROTECT MEDICAL, INC. | 1 | $15 |
Products named: GEMTESA, ADSTILADRIN, AVEED, JOURNAVX, LUPRON DEPOT, ORGOVYX, JELMYTO, PLUVICTO.
Industry payments across MD — which companies pay providers there.
